These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 20095429)

  • 41. IgG responses after booster vaccination with different pertussis vaccines in Dutch children 4 years of age: effect of vaccine antigen content.
    Hendrikx LH; Berbers GA; Veenhoven RH; Sanders EA; Buisman AM
    Vaccine; 2009 Nov; 27(47):6530-6. PubMed ID: 19729085
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Why do pertussis vaccines fail?
    Cherry JD
    Pediatrics; 2012 May; 129(5):968-70. PubMed ID: 22529282
    [No Abstract]   [Full Text] [Related]  

  • 43. Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis.
    Giuliano M; Mastrantonio P; Giammanco A; Piscitelli A; Salmaso S; Wassilak SG
    J Pediatr; 1998 Jun; 132(6):983-8. PubMed ID: 9627590
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Number and order of whole cell pertussis vaccines in infancy and disease protection.
    Sheridan SL; Ware RS; Grimwood K; Lambert SB
    JAMA; 2012 Aug; 308(5):454-6. PubMed ID: 22851107
    [No Abstract]   [Full Text] [Related]  

  • 45. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis.
    Storsaeter J; Hallander HO; Gustafsson L; Olin P
    Vaccine; 1998 Dec; 16(20):1907-16. PubMed ID: 9796042
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dot immunoassay for the simultaneous determination of postvaccination immunity against pertussis, diphtheria, and tetanus.
    Khramtsov P; Bochkova M; Timganova V; Zamorina S; Rayev M
    Anal Bioanal Chem; 2017 Jun; 409(15):3831-3842. PubMed ID: 28374129
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lipopolysaccharide analogs improve efficacy of acellular pertussis vaccine and reduce type I hypersensitivity in mice.
    Geurtsen J; Banus HA; Gremmer ER; Ferguson H; de la Fonteyne-Blankestijn LJ; Vermeulen JP; Dormans JA; Tommassen J; van der Ley P; Mooi FR; Vandebriel RJ
    Clin Vaccine Immunol; 2007 Jul; 14(7):821-9. PubMed ID: 17494641
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Different IgG-subclass distributions after whole-cell and acellular pertussis infant primary vaccinations in healthy and pertussis infected children.
    Hendrikx LH; Schure RM; Oztürk K; de Rond LG; de Greeff SC; Sanders EA; Berbers GA; Buisman AM
    Vaccine; 2011 Sep; 29(40):6874-80. PubMed ID: 21803088
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of 13 acellular pertussis vaccines: overview and serologic response.
    Edwards KM; Meade BD; Decker MD; Reed GF; Rennels MB; Steinhoff MC; Anderson EL; Englund JA; Pichichero ME; Deloria MA
    Pediatrics; 1995 Sep; 96(3 Pt 2):548-57. PubMed ID: 7659475
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of efficacy in terms of antibody levels and cell-mediated immunity of acellular pertussis vaccines in a murine model of respiratory infection.
    Watanabe M; Komatsu E; Sato T; Nagai M
    FEMS Immunol Med Microbiol; 2002 Jul; 33(3):219-25. PubMed ID: 12110485
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine.
    Gustafsson L; Hallander HO; Olin P; Reizenstein E; Storsaeter J
    N Engl J Med; 1996 Feb; 334(6):349-55. PubMed ID: 8538705
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age.
    Silfverdal SA; Assudani D; Kuriyakose S; Van Der Meeren O
    Hum Vaccin Immunother; 2014; 10(10):2795-8. PubMed ID: 25483640
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Detection of antibodies against fimbria type 3 (Fim3) is useful diagnostic assay for pertussis.
    Oguchi K; Miyata A; Kazuyama Y; Noda A; Suzuki E; Watanabe M; Nakayama T
    J Infect Chemother; 2015 Sep; 21(9):639-46. PubMed ID: 26134278
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunogenicity and safety of the quadrivalent meningococcal vaccine MenACWY-TT co-administered with a combined diphtheria-tetanus-acellular pertussis vaccine versus their separate administration in adolescents and young adults: A phase III, randomized study.
    Rivera L; Schwarz TF; Kim KH; Kim YK; Behre U; Cha SH; Jo DS; Lee J; Lee JS; Cheuvart B; Jastorff A; Van der Wielen M
    Vaccine; 2018 Jul; 36(31):4750-4758. PubMed ID: 29960800
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antigens in whooping cough vaccine and antibody levels induced by vaccination of children.
    Ashworth LA; Robinson A; Irons LI; Morgan CP; Isaacs D
    Lancet; 1983 Oct; 2(8355):878-81. PubMed ID: 6137697
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A phase I, randomized, controlled, dose-ranging study of investigational acellular pertussis (aP) and reduced tetanus-diphtheria-acellular pertussis (TdaP) booster vaccines in adults.
    Leroux-Roels G; Lattanzi M; Solis CD; Contorni M; Costantini M; Moraschini L; Bardelli M; Bertholet S; Borgogni E; Buricchi F; Cantisani R; Faenzi E; Finco O; Leuzzi R; Pizza M; Rosa D; Schiavetti F; Seubert A; Spensieri F; Volpini G; Zedda L; Giudice GD; Galgani I
    Hum Vaccin Immunother; 2018 Jan; 14(1):45-58. PubMed ID: 29172945
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cell-mediated and antibody responses to Bordetella pertussis antigens in children vaccinated with acellular or whole-cell pertussis vaccines. The Progetto Pertosse-CMI Working Group.
    Cassone A; Ausiello CM; Urbani F; Lande R; Giuliano M; La Sala A; Piscitelli A; Salmaso S
    Arch Pediatr Adolesc Med; 1997 Mar; 151(3):283-9. PubMed ID: 9080938
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Identifying long-term memory B-cells in vaccinated children despite waning antibody levels specific for Bordetella pertussis proteins.
    Hendrikx LH; Oztürk K; de Rond LG; Veenhoven RH; Sanders EA; Berbers GA; Buisman AM
    Vaccine; 2011 Feb; 29(7):1431-7. PubMed ID: 21187178
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Decennial administration of a reduced antigen content diphtheria and tetanus toxoids and acellular pertussis vaccine in young adults.
    Mertsola J; Van Der Meeren O; He Q; Linko-Parvinen A; Ramakrishnan G; Mannermaa L; Soila M; Pulkkinen M; Jacquet JM
    Clin Infect Dis; 2010 Sep; 51(6):656-62. PubMed ID: 20704493
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: An open, phase III, non-randomized, multi-center study.
    Kovac M; Kostanyan L; Mesaros N; Kuriyakose S; Varman M
    Hum Vaccin Immunother; 2018; 14(8):1977-1986. PubMed ID: 29630439
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.